Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for Monday's trading.
Calderoni touted Red Hat's partnership with Amazon.com (AMZN) and the recently announced partnership with Microsoft (MSFT) as proof of his company's ability to deliver the software companies need. Red Hat currently calls 90% of the Fortune 500 customers.
When asked about the company's ability to grow, Calderoni noted it finds customers typically start small but over time use more of Red Hat's services. So there is plenty of room to grow.
Whether it's customers moving from Windows to Linux or from free Linux to paid Linux, there is no shortage of new customer trying Red Hat software.
Cramer said he remains a fan of Rad Hat.
Isis Pharmaceuticals (ISIS) : In his second "Executive Decision" segment, Cramer checked in with Dr. Stanley Crooke, chairman and CEO of Isis Pharmaceuticals, which announced Friday it has changed its name to Ionis Pharmaceuticals and will trade under the ticker IONS next week.
Dr. Crooke said the new name takes away one of the distractions affecting the company at a time when there are a lot of exciting things going on, including three Phase III trials for his company's cancer, cardiovascular and metabolic disorder treatments.
Crooke touted his company's partnership with AstraZeneca, which began on their cancer treatments and has now expanded to cardiovascular collaboration as well. He also noted GlaxoSmithKlein (GSK) as another significant partner for Ionis.
Cramer said the new Ionis has a lot cooking beside its new name.
AstraZeneca (AZN) and Cummins (CMI) : When analysts change their minds, investors should take notice, Cramer told viewers. That's why he examined the sell-to-buy change of heart at Morgan Stanley (MS) of AstraZeneca and the simultaneous buy-to-sell call by Bank of America (BAC) of Cummins.
In the first report, the analyst patted himself on the back for advising investors to sell AstraZeneca going into 2015. Shares underperformed the markets by 10%. But now he advised them to buy, buy, buy as the company is expecting three Phase III trial results in 2016, along with three new drugs hitting the market.
In the case of Cummins, the analyst noted that the engine maker will continue to struggle against foreign competition given the strong U.S. dollar, giving investors little hope without a recovery in China.
What was Cramer's take? He said he's a buyer of AstraZeneca but as for Cummins, he feels that stock may be hitting bottom as it approaches a 5% yield.
To read a full recap of "Mad Money" on CNBC, click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.